Ascent Group LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 52.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 49,324 shares of the biopharmaceutical company's stock after buying an additional 17,016 shares during the quarter. Ascent Group LLC's holdings in Gilead Sciences were worth $5,469,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Southland Equity Partners LLC raised its position in Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company's stock valued at $364,000 after buying an additional 92 shares during the last quarter. Twelve Points Wealth Management LLC grew its stake in Gilead Sciences by 1.5% in the 2nd quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company's stock valued at $721,000 after purchasing an additional 98 shares during the period. Argentarii LLC grew its stake in Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after purchasing an additional 99 shares during the period. Perkins Coie Trust Co grew its stake in Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after purchasing an additional 100 shares during the period. Finally, Investment Research & Advisory Group Inc. grew its stake in shares of Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 100 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences Stock Up 1.9%
Shares of NASDAQ:GILD opened at $112.69 on Friday. The stock has a fifty day simple moving average of $114.34 and a two-hundred day simple moving average of $109.92. The stock has a market capitalization of $139.83 billion, a price-to-earnings ratio of 22.45, a PEG ratio of 0.75 and a beta of 0.34. Gilead Sciences, Inc. has a 12-month low of $83.98 and a 12-month high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same quarter in the previous year, the business earned $2.01 earnings per share. The company's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's payout ratio is currently 62.95%.
Insider Buying and Selling at Gilead Sciences
In other news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the transaction, the insider owned 113,193 shares of the company's stock, valued at $12,855,329.01. This represents a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the transaction, the chief executive officer directly owned 591,203 shares of the company's stock, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,000 shares of company stock valued at $9,402,130. Company insiders own 0.27% of the company's stock.
Analysts Set New Price Targets
A number of analysts recently issued reports on GILD shares. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a report on Friday, July 25th. Weiss Ratings reissued a "buy (b)" rating on shares of Gilead Sciences in a report on Saturday, September 27th. UBS Group raised their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Finally, Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $117.17.
Get Our Latest Analysis on Gilead Sciences
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report